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Background: Early detection and effective management of risk factors can potentially delay progression of chronic
kidney disease (CKD) to end-stage kidney disease, and decrease mortality and morbidity from cardiovascular (CV)
disease. We evaluated a specialist nurse-led intervention in the primary care setting to address accepted risk factors
in a study sample of adults at ‘high risk of CKD progression’, defined as uncontrolled type II diabetes and/or
hypertension and a history of poor clinic attendance.
Methods: The study was a non-controlled quality improvement study with pre- and post- intervention comparisons
to test feasibility and potential effectiveness. Patients within two primary care practices were screened and recruited to
the study. Fifty-two patients were enrolled, with 36 completing 12-months follow-up. The intervention involved a series
of sessions led by the nephrology Nurse Practitioner with assistance from practice nurses. These sessions included
assessment, education and planned medication and lifestyle changes. The primary outcome measured was proteinuria
(ACR), and the secondary outcomes estimated glomerular filtration rate (eGFR) and 5-year absolute CV risk. Several
‘intermediary’ secondary outcomes were also measured including: blood pressure, serum total cholesterol, glycosylated
haemoglobin (HbA1c), body mass index (BMI), prevalence of active smoking, a variety of self-management domains,
and medication prescription. Analysis of data was performed using linear and logistic regression as appropriate.
Results: There was a significant improvement in ACR (average decrease of −6.75 mg/mmol per month) over the
course of the study. There was a small but significant decrease in eGFR and a reduction in 5 year absolute CV
risk. Blood pressure, serum total cholesterol, and HbA1c all decreased significantly. Adherence to lifestyle advice
improved with a significant reduction in prevalence of active smoking, although there was no significant change
in BMI. Self-management significantly improved across all relevant domains.
Conclusions: The results suggest that a collaborative model of care between specialist renal nurses and primary
care clinicians may improve the management of risk factors for progression of CKD and CV death. Further larger,
controlled studies are warranted to definitively determine the effectiveness and costs of this intervention.
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Chronic kidney disease (CKD) is a global public health
issue. In New Zealand, end stage kidney disease (ESKD)
alone accounts for 1-2% of total health care expenditure,
a figure comparable to that in the United Kingdom [1,2].
The group with highest attributable risk of progressive
CKD is those with diabetes mellitus, and this risk is ex-
acerbated by hypertension, obesity and dyslipidaemia
[3,4]. In addition, CKD is an independent risk factor for
cardiovascular (CV) morbidity and mortality through
reduced glomerular filtration rate (GFR) and protein-
uria [5,6]. In New Zealand, indigenous groups (Maori
and Pacific peoples) are over represented in their rates
of ESKD, accounting for 44% and 29% of those com-
mencing renal replacement therapy in New Zealand,
respectively [7]. These indigenous groups also have
highest prevalence of CKD and associated risk factors
for progression.
It is generally accepted that early detection and ef-
fective management of CKD is the prime strategy to
reduce progression to ESKD, decrease CV morbidity and
mortality, and ultimately limit resource consumption
[3,8-10]. However despite this knowledge, efforts to man-
age CKD have not proven effective and the number of
patients reaching ESKD continues to increase. Within
New Zealand, there are numerous reported barriers that
hamper effective management of CKD in the community
including socio-economic factors, poor accessibility to
primary care, poor health literacy, lack of knowledge of
CKD and sub-optimally controlled diabetes and blood
pressure [11,12]. Alternative models of healthcare deliv-
ery are needed to address these issues.
A promising intervention is adjunctive support from
nephrology Nurse Practitioners (NPs), which has been
recently shown to reduce the rate of CKD progression
and improve renal outcomes [13]. Although this interven-
tion can be regarded as multifaceted, a key element in the
role of NPs is coaching to improve self-management by
patients. Although the researchers in the aforementioned
study did not assess for change in self-management, there
have been other randomized control trials (RCTs) involv-
ing specifically designed self-management interventions
for CKD patients. These have shown measurable improve-
ments in health behaviours and a reduction in the dur-
ation and number of hospital admissions [14], although a
recent systematic review of literature has highlighted the
small effect of self-management interventions upon level
of adherence [15].
In 2010 the New Zealand Ministry of Health funded sev-
eral initiatives to improve outcomes for New Zealanders
with CKD through more effective management in the pri-
mary care setting. In New Zealand, secondary and tertiary
services such as nephrology are provided free of charge to
all patients through public hospitals funded by taxation.By contrast, primary care (where most CKD is managed)
is provided in private medical practices, where consulta-
tions are only partially publicly subsidized. In this article,
we describe a quality improvement intervention involving
collaboration between a regional nephrology service and
local primary care clinicians to manage a group of patients
with CKD at high risk of progression. The intervention
utilized the resource of a nephrology NP, who in New
Zealand is a highly-trained specialist nurse practicing
autonomously and able to assess, diagnose and pre-
scribe within their scope of practice [16]. The Ministry of
Health funded the time of the NP working with clinicians
in their primary care practice, thus enabling the service to
be free to the patients.
In this study, we present an evaluation of this inter-
vention in order to demonstrate the clinical potential
of the model of care. We employed the reporting
framework suggested by the Standards for Quality Im-
provement Reporting Excellence (SQUIRE) publication





The study was approved by the Regional Ethics Committee
(IRB00008714) of the New Zealand Ministry of Health
(IORG0000895), conditional upon local ethics committee
approval which was granted by the Institutional Review
Board of the Hawke’s Bay District Health Board after a
full review of the study protocol. Patients were invited
to participate in the intervention, given verbal and writ-
ten information regarding the study and what their in-
volvement would include, and informed that they were
able to withdraw from participation at any stage.
Setting
The geographical setting for this study was Hawke’s Bay,
New Zealand, a rural district situated on the east coast
of New Zealand with a population of approximately
170,000. The population of Hawke’s Bay is notable
for a high degree of socioeconomic deprivation, with
26% of the population in the lowest two national
deciles of deprivation. The area is also notable for a
high prevalence of New Zealand Maori (the indigenous
ethnic group), comprising 25% of the population compared
to 15% nationally.
The intervention in this study was conducted by
Hawke’s Bay District Health Board Nephrology Service
in collaboration with two primary care practices located
in the highest areas of socioeconomic deprivation in
the region. Each practice served a catchment at the
time of between 5000–7000 people, with clinicians that
included General Practitioners (GPs) and practice nurses,
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practice.
Patients were studied over a 12 month period, with an
accrual period from 1st June 2011 to 15th September
2011.
Planning the intervention
Patients were screened and recruited through the pri-
mary care practices. Inclusion criteria required that all
of the following conditions were met: ‘high risk of CKD
progression’ (as defined below), age >18 years, diag-
nosis of type two diabetes mellitus, hypertension, and54 invited to parcipate






Figure 1 Patient flow.albuminuria defined as an albumin to creatinine ratio
(ACR) >30 mg/mmol on at least three occasions separated
by at least 1 week [18]. The main exclusion criterion was
CKD due to renal parenchymal disease other than diabetic
nephropathy. Patients at "high risk of CKD progression"
were defined as those with at least 12 months of uncon-
trolled diabetes and/or hypertension (glycoslyated haemo-
globin (HbA1c) >8% and blood pressure (BP) >140/
90 mmHg [19,20]) and a history of poor attendance and
engagement with their GP (history of unplanned non-
attendance of 25% or more of scheduled appointments
over the course of 12 months). Over 500 patients werey
2 declined to parcipate
1 died, 2 withdrew due to severe 
intercurrent illness, 3 paents moved district
5 paents lost to follow up
1 paent lost to follow up
4 paents lost to follow up




Practice A 28 (54)
B 24 (46)
Age Years 57.5 (47–64)











Appropriate secondary specialist care 15 (29)
Total chronic medical illness burden CIRS Score 6.92 (2.27)
2 or more diagnoses (CIRS domains) % 33
3 or more diagnoses (CIRS domains) % 3
4 or more diagnoses (CIRS domains) % 0
Albumin to creatinine ratio mg/mmol 34.9 (14.2-150.9)
5-year absolute cardiovascular risk % 20 (15–27)
Estimated GFR mL/min/1.73 m2 63 (48–77)
Systolic BP mmHg 150 (144.5-160)
Diastolic BP mmHg 90 (80–110)
Serum total cholesterol mmol/L 5.25 (4.1-6)
Glycosylated haemoglobin % 8.8 (7.7-10.7)
Body mass index kg/m2 37 (32.5-43.5)
Active smoking 18 (35)
Self-management Score
Overall score (scale 0 to 104) 82 (72–91)
Knowledge of medications (scale 0 to 8) 6 (5–8)
Knowledge of condition (scale 0 to 8) 6 (4–7)
Medication adherence (scale 0 to 8) 8 (5–8)
Healthy lifestyle (scale 0 to 8) 6 (4–8)
Prescribed aspirin % 31 (60)







All data are presented as n (%) or median (IQR).
Walker et al. BMC Family Practice 2014, 15:155 Page 4 of 14
http://www.biomedcentral.com/1471-2296/15/155identified from the initial screen within the practices
and fifty-four high risk patients were identified by the
primary care teams as also meeting the criteria for poor
attendance. These fifty-four were given written informa-
tion and invitation to participate by their GP or practice
nurse. All were subsequently re-contacted by phone to
answer any questions, and offered an initial assessment.
Fifty two patients subsequently enrolled and participated
in the study (Figure 1).
The intervention involved a series of sessions led by
the nephrology NP with the assistance of the practice
nurse. Patients were seen fortnightly for 12 weeks by the
NP and the practice nurse, followed by a monitoring
phase to 12 months. At baseline, a comprehensive pa-
tient history, health literacy and self-management assess-
ment, physical assessment, and laboratory review was
performed. Patient history included: medical history,
family and social history and lifestyle behaviours in-
cluding diet, smoking status, salt intake, exercise, and
current knowledge of condition and medication. Physical
assessment included office measurement of BP according
to standardised protocol (JNC 7 [21]), pulse, height,
weight, review of home capillary blood sugar records,
and clinical cardiac assessment, conducted by the NP.
Laboratory review included HbA1c, serum creatinine,
estimated glomerular filtration rate (GFR), ACR and
serum lipid levels.
Initial sessions involved tailored education and the
development of individualised care plans based on best
practice guidelines and using self-management and
patient-centered theory utilizing the Flinders Chronic
Care model [22]. A detailed patient education package
was developed for the study and included information
on diabetes and its complications, blood pressure man-
agement, lifestyle modifications, medication adherence,
smoking cessation and dietary advice including low salt
intake (dietary sodium intake less than 2.3 g/day). All
patients were also given a booklet on self-management
developed for the study where they could record all
clinical results, self-care goals, individualised medica-
tion charts and other important information.
Subsequent sessions involved implementation of the
individualized care plans, re-assessment of patients and
management plan changes and implementations as re-
quired. A stepwise BP protocol was developed for the
project with titration of antihypertensives at each fort-
nightly review to target a BP of 130/80 mmHg [19,20,23].
The protocol of medication escalation involved the step-
wise addition of angiotensin converting enzyme inhibitors
(ACEi) or angiotensin receptor blockers (ARB), thiazide
diuretic, calcium channel blocker, and beta blocker or
alpha blocker. Patients were provided with free transport
to their study appointments, and all medications subjected
to usual patient payments and subsidies without additionalcost or reimbursement. All patients in the study continued
to receive usual health care (appointments as requested by
patients or scheduled chronic disease management routine
appointments, which are in general less than 15 minutes
and 3 monthly at most) from their GP and primary health
care team. Patients underwent baseline and three monthly
Table 2 Frequency of New Zealand deprivation scores
Deprivation score Frequency Percent Cumulative percent
1 1 1.9 2.0
2 1 1.9 4.0
3 1 1.9 6.0
4 1 1.9 8.0
7 1 1.9 10.0
8 3 5.8 16.0
9 13 25.0 42.0
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vation. All patient information and results was entered dir-
ectly into the primary care health care record.
Planning the study of the intervention
We chose a validated method of measuring and describing
the co-morbidities and multi-morbidity in the patientTable 3 Change in observed outcome as a function of time
Primary outcome Change per unit p




5-year absolute cardiovascular risk
“Intermediary” secondary outcomes - participant
Systolic blood pressure (mmHg)
Diastolic blood pressure (mmHg)
Serum total cholesterol (mmol/L)
HbA1c (%)
BMI (kg/m2)
Active smoking (odds ratio)
Self-management
Overall score (scale 0 to 104)
Knowledge of medications (scale 0 to 8)
Knowledge of condition (scale 0 to 8)
Medication adherence (scale 0 to 8)
Healthy lifestyle (scale 0 to 8)
“Intermediary” secondary outcomes - provider
Prescribed aspirin (odds ratio)
Prescribed ACEi/ARB (odds ratio)
Prescribed HMG-CoA reductase inhibitors (odds ratio)
Number of prescribed anti-hypertensivescohort. We extracted co-morbidity data from the medical
history of patient records, and classified multi-morbidity
using the Cumulative Illness Rating Scale (CIRS) [24]. This
scale has been validated and applied in primary care set-
tings, and has been used widely including the Australasian
setting [25]. The scale rates the presence and severity of
illness in 14 organ systems to provide an index of total
chronic medical illness burden [26]. In this study, we
assessed multimorbidity using 3 operational definitions:
namely, 2 or more diagnoses (or CIRS domains), 3 or more
diagnoses (or CIRS domains), and 4 or more diagnoses (or
CIRS domains). We assessed the socioeconomic status of
the patient cohort using the NZDep score, which combines
nine variables from the census that reflect eight domains
of deprivation (income, home ownership, social support,
employment, academic qualifications, living space, access
to a telephone, access to a car). The index provides a score
for each meshblock in New Zealand, which are defined
geographical areas defined by Statistics New Zealand con-
taining a median number of approximately 87 people in
2006. The NZDep score divides New Zealand into deciles,
e.g. a value of 10 indicates the meshblock is in the most de-
prived 10% of the New Zealand population, and a value of
1 indicates that the meshblock is in the least deprived [27].er month (linear), or change
onth (binary categories)
(95% Confidence Interval) P Value
−6.75 −10.98, −2.52 0.002
−0.34 −0.55, −0.12 0.002
−0.24 −0.40, −0.09 0.002
−1.65 −2.02, −1.28 <0.01
−1.07 −1.33, −0.81 <0.001
−0.05 −0.08, −0.02 0.002
−0.09 −0.13, −0.06 <0.001
−0.06 -.13, −0.008 0.08
0.69 0.54, 0.88 0.003
1.11 0.72, 1.50 <0.001
0.17 0.12, 0.22 <0.001
0.14 0.10, 0.18 <0.001
0.05 0.001, 0.09 0.044
0.06 0.02, 0.11 0.005
1.61 1.23, 2.11 <0.001
1.97 1.04, 3.72 0.037
1.26 1.08, 1.46 0.003
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Figure 2 Primary and secondary outcomes: albumin to creatinine ratio (mg/mmol), estimated GFR (mL/min/1.73 m2) and 5 year
absolute cardiovascular risk (%) over the period of observation. Individual participant trajectories are illustrated in the overlaid line plots in
the left panels, and the trajectory for the cohort in the boxplots in the right panels (the central line represents the median, the box the first and
third quartile, and the whiskers 1.5 × the interquartile range).
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Figure 3 (See legend on next page.)
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(See figure on previous page.)
Figure 3 ‘Intermediary’ secondary outcomes related to the patient: BP (mmHg), serum total cholesterol, BMI (kg/m2), HbA1c (%),
prevalence of active smoking over the period of observation. For continuous variables, individual participant trajectories are illustrated in the
overlaid line plots in the left panels, and the trajectory for the cohort in the boxplots in the right panels (the central line represents the median,
the box the first and third quartile, and the whiskers 1.5 × the interquartile range). For categorical variables, bar plots indicate proportions for the
entire cohort.
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improvement program through the attendance of the
participants to appointments, the attendance of both the
NP and the practice nurse for the combined clinics, and
staff satisfaction.
We measured the overall clinical impact of the quality
improvement program through assessment of study out-
comes over the 12 month period of the intervention.
Measurements of outcomes (other than for health know-
ledge, medication knowledge, and self-management) were
made at baseline, and endpoints consisted of measure-
ments at 3, 6, 9 and 12 months. Measurements of health
knowledge, medication knowledge, and self-management
were made at baseline, and endpoints consisted of mea-
surements at 3 and 12 months.
The primary outcome was proteinuria, assessed as the
ACR on a random urine specimen taken prior to or at
the combined clinic consultation. The secondary out-
comes were: estimated GFR as assessed from serum
creatinine and the 175 4-variable MDRD equation [28]
(which to date remains the standard method rather than
the CKD-EPI formula throughout New Zealand), and
5-year absolute cardiovascular risk (defined as the likeli-
hood of a cardiovascular event over 5 years) [23].
We also assessed ‘intermediary’ secondary outcomes.
These outcomes were either related to processes of care,
or related to clinical outcomes accepted as being inter-
mediate on casual pathways leading to either progression
of CKD or to increased cardiovascular risk. Such outcomes
were chosen as being the most likely mechanisms through
which the study intervention might improve outcomes.
For intermediary secondary outcomes related to the
participant, we assessed BP according to standardised
protocol (JNC 7 [21]), serum total cholesterol, BMI,
HbA1c and the prevalence of active smoking through
patient clinical records. We assessed overall self-
management, overall medical knowledge (knowledge of
condition and medication), adherence to medication and
adoption of a healthy lifestyle through a self-management
reporting scale (Partners In Health Score, PIH score)
[29]. The PIH score and questionnaire was developed for
the Australian healthcare context, and is used to assess
changes in patient self-management knowledge, skill and
ability. The assessments are made from both the patient’s
own perspective and from the perspective of the treating
clinician. The ratings span across twelve domains, orareas of patient knowledge and health-related behaviour.
The PIH scores provide a validated longitudinal record of
how well patients are coping with and managing their
chronic conditions [29].
For intermediary secondary outcomes related to the
provider, we assessed prescribing patterns through pa-
tient clinical records.
Laboratory measurements were made in a central la-
boratory using standardized equipment (Abbott Aeroset®,
Abbott Laboratories (N.Z.) Limited, Auckland, New
Zealand). Serum creatinine assays were performed using
the Jaffe method, and calibrated to isotope dilution mass
spectroscopy.
Methods evaluation and analyses
The study data are in the form of a cross-sectional time-
series, otherwise known as a panel, with repeated clinical
observations obtained from the same patient over time.
The data produce an unbalanced panel, as a result of miss-
ing observations pertaining to both truly missing data and
also observations that are recorded during some months
but not others. Of note, all study data from all participants
were modelled, including baseline and follow-up results for
those who died and dropped out, up until the time of their
termination within the study.
We conducted the analysis of study data using regression
models within Stata 12.1 MP software (College Station,
TX, USA). For continuous data, we used linear models
(xtreg procedure) and for categorical ones we used logistic
models (xtlogit procedure). To account for internal correl-
ation between repeated patient observations, a random
effect model was used for each dependent variable that in-
cluded all data from all time periods simultaneously, with
observations over time from the same patient sharing the
same random effects, assuming different random effects
for different patients. To account for non-response bias, re-
gression coefficients were estimated using the maximum
likelihood method. Time was modelled as a continuous
variable, and all coefficients are the modelled change in
each parameter per month, with the p value referring to
the significance of this change over time.
Results
Participants
Of the original 52 participants, 36 were still available for
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Figure 4 (See legend on next page.)
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(See figure on previous page.)
Figure 4 ‘Intermediary’ secondary outcomes related to the patient: self-management, medical knowledge (knowledge of condition
and medication), adherence to medication, and adoption of a healthy lifestyle over the period of observation. Individual participant
trajectories are illustrated in the overlaid line plots in the left panels, and the trajectory for the cohort in the boxplots in the right panels (the
central line represents the median, the box the first and third quartile, and the whiskers 1.5 × the interquartile range).
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and details of their total chronic medical illness burden
in Additional file 1: Table S1. Socio-economic status of
participants is described in Table 2, and illustrates the
high level of deprivation with 84% of participants living
in the 9 or 10th decile.
Course and success in implementation of intervention
Attendance of both the NP and the practice nurse
was required as an integral component of the study
intervention, and was 100% for the combined clinics.
Staff satisfaction was surveyed as a routine part of clinical
operations at the primary care practices, and was re-
ported as high for all practice nurses and GPs involved in
this initiative. All patients who were lost to follow up ei-
ther died, withdrew due to severe intercurrent illness
(one stroke, one myocardial infarction), or moved out of
the district. ‘Did not attend’ rates were less than 5% for
all participants remaining eligible over the entire period
of observation.
Outcomes
Results of regression modelling and rank sum testing for
study outcomes are provided in detail in Table 3.
There was a significant change in the primary out-
come, ACR, over the course of the study, amounting to
an average decrease of −6.75 mg/mmol per month over
the period of observation. There were also significant
changes in the secondary outcomes. There was a signifi-
cance decrease in estimated GFR of −0.3 mL/min/
1.73 m2 per month, indicating that progression of CKD
was still occurring within the study cohort amounting to
a loss of 3–4 mL/min/1.73 m2 per annum. There was a
significant decrease in the 5 year absolute cardiovascular
risk by −0.2% per month. Changes in these primary and
secondary outcomes are illustrated in Figure 2.
There were significant changes in intermediary sec-
ondary outcomes related to the participant. Blood
pressure decreased significantly over the course of the
study, with a median baseline measurement of 150/90
and a corresponding 12 month measurement of 132/
76. Serum total cholesterol and HbA1c also decreased
significantly, with median baseline measurements of
5.25 mmol/L and 8.75%, respectively, and corresponding
12 month measurements of 4.6 mmol/L and 7.55%,
respectively. Adherence to lifestyle advice improved,
with a significant decrease of active smoking from 35%to 10%, although there was no significant change in
BMI. Self-management significantly improved across
all relevant domains, with an increase in median over-
all self-management score from 82 to 99 over the
period of observation. These changes are illustrated in
Figures 3, 4 and 5.
There were significant changes in intermediary second-
ary outcomes related to the provider. The prescription of
ACEi/ARBs, aspirin and lipid lowering medications, in-
creased significantly to 97%, 86%, and 80% respectively.
The mean number of prescribed anti-hypertensives in-
creased significantly from 2 to 3.
Discussion
This report evaluates a primary care based intervention
for CKD patients at high risk of CKD progression. The
intervention utilized the nephrology NP within this set-
ting to improve risk factors for progression of CKD. The
baseline data for this group of participants indicated
sub-optimal management for an extended period of time,
with clinical care and outcomes that were not meeting cus-
tomary targets suggested in clinical practice guidelines.
Such characteristics define a common, problematic group
of patients, both within New Zealand and internationally.
One study from the United Kingdom typifies this experi-
ence, with only a fifth of those with diabetes and CKD hav-
ing a BP of 130/80 mmHg or less, and fewer than half on
angiotensin-converting-enzyme inhibitor or angiotensin-
receptor blocker [30]. Similar findings have been reported
from the United States [31].
This study supports the feasibility and potential effect-
iveness of an integrated model of care for management
of CKD. During the course of the nurse-led intervention
there was improved control of accepted risk factors for
progression of CKD. Patient adherence to medication
and lifestyle advice both improved over the duration of
the intervention, indicating that high risk patients are
sometimes willing to engage in lifestyle modifications
when afforded adequate support and education about
management of their condition, combined with empower-
ment through improved self-management skills.
Several other studies have shown similar success.
An algorithm-based, primary care disease-management
programme for patients with CKD in the United Kingdom
also associated with better control of BP, lower serum
cholesterol, and reduced the rate of kidney function loss
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Figure 5 ‘Intermediary’ secondary outcomes related to the provider: prescription of angiotensin converting enzyme inhibitors (ACEi)
or angiotensin receptor blockers (ARB), aspirin and lipid lowering medications, and number of antihypertensive medications. For
continuous variables, individual participant trajectories are illustrated in the overlaid line plots in the left panels, and the trajectory for the cohort
in the boxplots in the right panels (the central line represents the median, the box the first and third quartile, and the whiskers 1.5 × the
interquartile range). For categorical variables, bar plots indicate proportions for the entire cohort.
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community based (but not primary care based) initiative
within New Zealand has also reported similar results in
this population, with improvements in both renal and car-
diac endpoints [33]. A RCT involving intensified NP in-
volvement reduced the decline in kidney function and
improved renal outcomes in patients with prevalent CKD
over a sustained follow-up period [13].
The intervention described in this study involved col-
laboration between the regional secondary nephrology
service and primary care practices. The nephrology NP
worked primarily with practice nurses in the GP prac-
tices, with liaison with GPs as required. Interactions
between these clinicians allowed for education around
best practice and evidence-based management of CKD,
and provided opportunities for learning through case re-
views. This collaborative model also had the effect of
enhancing the currently limited linkages between these
primary care practices and the secondary nephrology
service in the region.
There is no study in the literature that can be used to
determine effect size between improved self-management
and improved clinical outcomes. Other studies have
assessed self-management as an outcome in itself, but only
two have assessed effect on patient-centred outcomes such
as HRQoL [34,35]. Ours is the first to have assessed effect
on clinical outcomes. One could question the clinical sig-
nificance of the small improvement in self-management
that we observed in this study, although we note that as
with other studies that there is sustained improvement of
clinical markers over time, suggesting a sustained and
long-term effect that might persist and even increase be-
yond the period of observation in this study [13]. The im-
provement in clinical outcomes observed in this study are
small but significant. For instance, although the decrease
in the 5 year absolute cardiovascular risk seems small
at −0.2% per month, this is equivalent to a 1.2% annual de-
crease in the risk of a cardiovascular event for this study
sample. This effect should be considered in the light of the
global burden of diabetic patients with CKD, which is the
primary diagnosis causing kidney disease in 20–40% of
people starting treatment for ESKD [36]. The rates of pro-
gression of newly diagnosed type 2 diabetics between the
stages of normoalbuminuria, microalbuminuria, macroal-
buminuria and kidney failure are 2–3% per year, as evi-
dences in the United Kingdom Prospective Diabetes Study
[37]. The annual mortality rate in this population is ap-
proximately 7% [38], and at least 50% of these deaths will
be cardiovascular in nature. As such, a seemingly small
1-2% annual decrease in the risk of cardiovascular mor-
bidity and mortality has the potential to avert many
life-years lost, and many health-dollars spent.
The total cost of the pilot was $160,000 over two
years, this included; NP and practice nurse release time,payment for GP’s and nurses to attend regular planning
meetings, patient transport, blood tests, administration
costs, clinical and electronic equipment and support,
printing and development of resources, administration
and reporting time. A large proportion of the cost was
used in planning the pilot in the six months prior. Fur-
ther studies should provide more detailed cost benefit
analysis.
The success of the intervention suggests a goal for sec-
ondary nephrology services, in using their expertise to
up-skill primary care clinicians to better manage CKD.
There are several ways in which primary care practices
can limit the growth of ESKD. Most importantly, prac-
tices can better screen their patient populations to iden-
tify those at different levels of risk, and work to apply
evidence-based medicine to improve risk factor man-
agement amongst those with CKD. There are several
major financial barriers to the scaling and implementa-
tion of programs such as the intervention in this study.
The main ones relate to the impact on primary health
care clinicians’ work, and the corresponding impact for
nephrology NPs who spend time away from their cus-
tomary duties in secondary care. Self-management edu-
cation should be included in all aspects of primary care
and CKD management as they have proven success-
ful in improving adherence outcomes in other chronic
conditions [39,40].
As a pilot intervention, this nurse-led intervention has
potential to limit growth of expensive renal replacement
therapy programmes. However, it was supported on a
time-limited basis by the New Zealand Ministry of
Health, with funding primarily to allow deployment of a
clinical resource, the nephrology NP, from secondary
into primary care. The service was therefore free to the
patients enrolled in the intervention, which we assume
contributed to their compliance with the requirements
of the programme. The feasibility of reproducing this
pilot on a larger scale with an economic benefit would
need to be further explored in future research. Making
publicly subsidized funding of primary care contingent
on clinical outcomes for practice populations may be
required to incentivize adoption of different clinical ac-
tivities. Financial incentive schemes employed in the
United Kingdom have been shown to potentially con-
tribute to the reduction in health inequalities in deprived
areas [41].
There are several limitations of study design. Firstly,
this study is a quality improvement initiative rather than
a randomized controlled trial, with no comparator group
or clinical data from the period prior to the intervention.
As such, there is risk of bias and confounding, and no
absolute certainty that the improvements were the
direct results of the intervention. It is possible that
they arose due to a separate and unrecognized co-
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arose from “regression to the mean” in our study sample,
which can occur when subjects are selected with out-
come measures at the extremes of a given distribution. In
this situation, the measures will tend to be closer to the
centre of the distribution on subsequent measurements,
which can often be incorrectly inferred as being an im-
provement in response to an intervention. The sampling
frame in this study (non-adherence over the prior one-
year period) reduces the risk of this occurrence, although
it remains a very definite, unquantifiable limitation on
the interpretation of our results. The second limitation of
the study design is that it is a small-scale project, and
cannot therefore be considered as proof of clinical effect-
iveness and cost effectiveness. Instead, the study demon-
strates the feasibility of this approach and potential
effectiveness. Finally, the study design did not include
data collection to evaluate change in the organizational
or clinical culture in primary care clinicians outside of
the intervention. As such, it is not possible to evaluate
whether the intervention was effective in institutionaliz-
ing a change in culture towards quality improvement in
CKD care [42].
There are several limitations of study analyses that
should also be acknowledged. Firstly, these were not
performed in a way that allowed for causal inference,
which would be the required approach to answer
questions such as “did changes in proteinuria result
from greater prescription of medication, or rather the
improved compliance of said medication?”. Such ana-
lyses may be possible using various structural model-
ling approaches, and will be considered further in the
future. Secondly, analyses assume linear relationships
over time, a prosaic approach to improve comprehen-
sibility of the statistical models. The analyses cannot,
however, address any non-linear relationships that might
have occurred over the period of observation. For in-
stance, the changes in many study variables show a pro-
nounced early improvement, with some “rebound” at a
later time. Notwithstanding, the models in this study do
provide an indication of the overall effect of the inter-
vention over the course of the study, and strongly sug-
gest that the benefits observed over 3 months were
sustained to a significant degree during the remainder
of the 12 months follow-up. Future studies are planned
to identify co-morbidities within the source population of
our study sample, to compare multi-morbidity between
the groups.
Conclusions
This study demonstrates that a model of specialist neph-
rology NP led clinics with primary care clinicians is feas-
ible and may improve risk factors for progression of CKD
and cardiovascular death. The cost of implementing suchas program a wider basis would be considerable, although
costs maybe offset in the long-term if the future burden of
ESKD is reduced. Notwithstanding, a collaborative ap-
proach to primary and secondary care may be an effective
way to manage high risk patients with CKD in the primary
care setting. The results of this study call for definitive
studies to definitively determine the effectiveness and
costs of this intervention in a controlled study on a wider
scale.
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